A Liquid Biopsy Analyst is a critical specialist in modern cancer diagnostics, focused on analyzing non-invasive samples—primarily blood—to detect and monitor cancer-related biomarkers. By examining circulating tumor DNA (ctDNA), RNA fragments, exosomes, and circulating tumor cells (CTCs), these analysts help uncover genetic mutations, gene fusions, and other molecular alterations linked to tumor growth and drug resistance. Utilizing advanced technologies such as digital PCR, next-generation sequencing (NGS), and high-throughput data analysis, Liquid Biopsy Analysts enable real-time insights into tumor dynamics without the need for traditional tissue biopsies. Their expertise allows for earlier cancer detection, therapy monitoring, and identification of emerging resistance, ultimately improving patient outcomes.
Liquid Biopsy Analysts play a key role in the development and validation of liquid biopsy assays, working closely with molecular pathologists, oncologists, and bioinformaticians. They interpret complex molecular data, contribute to personalized treatment planning, and support clinical trials focused on precision oncology. Their attention to quality control, assay accuracy, and emerging molecular techniques ensures that diagnostic results are both reliable and clinically actionable. As liquid biopsy continues to evolve as a transformative tool in oncology, the Liquid Biopsy Analyst remains at the forefront of innovation—bridging cutting-edge science with real-world application in the fight against cancer.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China